However, in people with diabetes, post-meal glucagon levels may be higher. High glucagon levels paired with not enough insulin in diabetes contribute to excess sugar production in the liver.

The global glucagon-like peptide-1 (GLP-1) agonists market was valued at USD 19.70 billion in 2024, driven by the rising prevalence of type 2 diabetes and obesity across the globe. The market is ...

The team also determined that glucagon-packed micelles stayed intact in mice and didn’t release the hormone unless blood glucose levels fell below the clinical threshold for severe hypoglycemia.

A balanced diet rich in high fiber foods, healthy fats, and vegetables is beneficial when taking GLP-1 medications. GLP-1 medications, or glucagon-like peptide-1 receptor agonists, treat type 2 ...

A new study led by Ananda Basu, M.D., used novel non-radioactive, stable glucagon tracers for the first time to characterize glucagon metabolism in humans with and without Type 1 diabetes, providing ...

MIT researchers have developed an implantable device that automatically releases glucagon to prevent dangerous hypoglycemia, offering a promising new safety net for people with diabetes. Image ...

Glucagon-like peptide-1 receptor (GLP-1R) agonists, originally developed for type 2 diabetes patients and popularized by their ability to rapidly reduce body weight in patients with obesity, have ...

About The Study: Glucagon-like peptide receptor agonists (GLP-1RAs) were associated with lower risks of specific types of obesity-associated cancers compared with insulins or metformin in ...

Opko Health and Entera Bio have formalized their partnership as the biotechs prepare to take the first orally administered dual agonist glucagonlike-peptide 1 (GLP-1)/glucagon peptide into the clinic.

Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management. Additional data on the efficacy and ...